You are here

Round table discussion on anaemia in cancer patients by Dr. Matti Aapro, Dr. Carla Ripamonti and Dr. Anton Snegovoy at the MASCC/ISOO Annual Meeting on 25 June 2015

MASCC15 round table-HD

Anaemia in cancer patients is an issue that needs a sophisticated approach, and there have been recent changes in the guidelines. NICE, the National Institute for Health and Care Excellence in the UK, has decided to accept the use of erythropoietins in chemotherapy-treated anaemic cancer patients.

In the USA, the costs for treating anaemia have increased with the use of erythropoiesis-stimulating agents (ESA). Dr. Ripamonti reports on an Italian study in which the costs of transfusions have decreased.

Dr. Snegovoy stresses the importance of establishing a proper diagnosis before starting anaemia treatment.

Dr. Matti Aapro, Clinique de Genolier, Genolier, Switzerland

Dr. Carla Ripamonti, Department of Hematology and Pediatric Onco-Hematology, Fondazione IRCCS, Istituto Nazionale Tumori Via Venezian, Milan, Italy

Dr. Anton Snegovoy, Department of Out-patient Chemotherapy, N.N. Blokhin Russian Cancer Research Center, RAMS, Moscow, Russia

Search this site

Featured videos

Free access to ebooks on cachexia and CINV

 

Prevention of nausea and vomiting in
adult cancer patients receiving tumour-
directed therapy – 2017 update –

and
Cancer cachexia: mechanisms and progress in treatment

 

Stay up-to-date with our monthly e-alert

If you want to regularly receive information on what is happening in Quality of Life in Oncology research sign up to our e-alert.

Subscribe »

QOL (Quality of Life) newsletter e-alert

Quality of Life promotional video

Made possible by an educational grant from Helsinn

Helsinn does not have any influence on the content and all items are subject to independent peer and editorial review

Society Partners

European Cancer Organisation Logo

Share